Teva said on Wednesday U.S. health authorities approved its generic version of Merck's osteoporosis treatment Fosamax. If history holds, prices for the generic medication, called alendronate, should run 40% to 60% less than the $90 a month Fosamax tends to cost.
The branded product had annual U.S. sales of about $1.9 billion in the 12 months ended Sept. 30, according to IMS sales data.
Teva has been awarded a 180-day period of marketing exclusivity.
Reuters
No comments:
Post a Comment